Risk Factors of Complications After Uterine Artery Embolisation for Symptomatic Fibroids: A Case-Control Study
- PMID: 39618017
- PMCID: PMC11794057
- DOI: 10.1111/1471-0528.18023
Risk Factors of Complications After Uterine Artery Embolisation for Symptomatic Fibroids: A Case-Control Study
Abstract
Objective: We aim to clarify potential risk factors of complications after uterine artery embolisation (UAE).
Setting: Complications after uterine artery embolisation (UAE) for symptomatic fibroids are rare, but failure of treatment occurs for approximately 13%-24% of patients at 10 years.
Design: We conducted a case-control study including all complications post UAE over 15 years in our specialised unit.
Population: All Grade 2 complications (or worse) for the Society of Interventional Radiology Standards of Practice Committee complications post UAE were considered. One thousand one hundred seventy-two UAE were performed.
Methods: Complications were divided into two groups: early (< 1 month) or late (≥ 1 month) to differentiate complications from failure of procedure. Multinomial analysis was conducted to assess links between complications and potential risk factors.
Results: Sixty-nine (0.06%) complications were found: 24.6% hospitalisation for pain (n = 17/69), 30.4% for infection (n = 21/69) and 2.9% expulsion of fibroid (n = 2/69). Overall, 31 patients underwent a second procedure (45%).
Main outcome measures: Intra-uterine device and multiple fibroids were strongly related to early complications (ORearly = 4.44, IC 95%: 1.5-13.3 and ORearly = 3.7, IC 95%: 1.2-11.3, respectively). The only factor that appeared to be associated with risk of early and late complications was the major fibroid's diameter (for an increased size of 25 mm, ORearly = 1.7, IC 95%: 1.1-2.6; ORlate = 1.5, IC 95%: 1.04-2.2).
Conclusion: Our study enlightens about the potential risk factors of UAE's complications and differentiate their impact between early and late complications.
Keywords: complications; fibroids; risk factors; uterine artery complications.
© 2024 The Author(s). BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
Conflict of interest statement
The ICMJE were provided. Pr Herbreteau and Pr Marret have a past of conflict of interest.
Figures
References
-
- Stewart E. A., Cookson C. L., Gandolfo R. A., and Schulze‐Rath R., “Epidemiology of Uterine Fibroids: A Systematic Review,” BJOG: An International Journal of Obstetrics & Gynaecology 124, no. 10 (2017): 1501–1512. - PubMed
-
- Kahn V., Pelage J. P., and Marret H., “Uterine Artery Embolization for Myomas Treatment,” Presse Médicale 42, no. 7–8 (2013): 1127–1132. - PubMed
-
- Marret H., Fritel X., Ouldamer L., et al., “Therapeutic Management of Uterine Fibroid Tumors: Updated French Guidelines,” European Journal of Obstetrics, Gynecology, and Reproductive Biology 165, no. 2 (2012): 156–164. - PubMed
-
- Brun J. L., Plu‐Bureau G., Huchon C., et al., “Prise en Charge des Ménorragies: Recommandations Pour la Pratique Clinique du Collège National des Gynécologues et Obstétriciens Français (CNGOF),” Gynécologie Obstétrique Fertil Sénologie 50, no. 5 (2022): 345–373. - PubMed
-
- NICE , “Recommendations,” in Heavy Menstrual Bleeding: Assessment and Management (London, UK: NICE, 2018).
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
